2-Methoxy-5-[3-(3,4,5-trimethoxyphenyl)triazol-4-yl]phenol | 1034292-85-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Methoxy-5-[3-(3,4,5-trimethoxyphenyl)triazol-4-yl]phenol
• CAS: 1034292-85-7
• 化学式: C₁₈H₁₉N₃O₅
• 分子量: 357.366
• InChiKey: DCEBFZXQYUBEHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  87.9
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-叔-丁基二甲基硅氧基-4-甲氧基苯甲醛 在 四丁基氟化铵 、 乙基氯化镁 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 7.5h， 生成 2-Methoxy-5-[3-(3,4,5-trimethoxyphenyl)triazol-4-yl]phenol
  参考文献：
  名称：

  Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A–1

  摘要：

  The antiproliferative activity on ovarian cancer (SK-OV-3) cells of a series of triazole-bridged combretastatin analogues (37, 38, 40-43) containing dihalogenation of the A-ring is reported, and compared with their trimethoxy analogues (5, 15, 39). It was found that dihalogenation with either bromine or iodine was a tolerated modification when compared to the parent compound combretastatin (CA-4, 1) and had less effect than B-ring modification on potency. These compounds exhibited G(2)/M arrest, and maintained antitubulin activity. Further assays on human umbilical vein endothelial cells (HUVECs) demonstrated the potential antivascular effects of these triazoles. Of particular note was a 3,5-diiodo-4-methoxyaryl triazole (43) which had promising 7-fold selectivity for HUVECs over ovarian cancer cells. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.01.010

文献信息

• 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin
  作者：Kristin Odlo、Jean Hentzen、Jérémie Fournier dit Chabert、Sylvie Ducki、Osman A.B.S.M. Gani、Ingebrigt Sylte、Martina Skrede、Vivi Ann Flørenes、Trond Vidar Hansen

  DOI：10.1016/j.bmc.2008.03.049

  日期：2008.5

  1,5-disubstituted 1,2,3-triazole analogues of combretastatin A-4 (1) have been prepared. The triazole 12f, 2-methoxy-5-(1-(3,4,5-trimethoxyphenyl)-1H-1,2,3-triazol-5-yl)aniline, displayed potent cytotoxic activity against several cancer cell lines with IC(50) values in the nanomolar range. The ability of triazoles to inhibit tubulin polymerization has been evaluated, and 12f inhibited tubulin polymerization

  制备了康布雷他汀A-4（1）的一系列顺式限制1,5-二取代1,2,3-三唑类似物。三唑12f，2-甲氧基-5-（1-（3,4,5-三甲氧基苯基）-1H-1,2,3-三唑-5-基）苯胺对IC的几种癌细胞系表现出有效的细胞毒活性（50）值在纳摩尔范围内。已经评估了三唑抑制微管蛋白聚合的能力，并且12f以IC（50）= 4.8microM抑制微管蛋白聚合。涉及12f和秋水仙碱的α，β-微管蛋白结合位点的分子模型实验表明，三唑部分通过与几个氨基酸的氢键与β-微管蛋白相互作用。
• Compounds for the treatment of proliferative disorders
  申请人：Demko Zachary

  公开号：US20070238699A1

  公开（公告）日：2007-10-11

  The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein R a , R b , and R 2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.

  本发明涉及结构式（I）的化合物：或其药学上可接受的盐，溶剂化物，包合物和前药，其中Ra，Rb和R2在此定义。这些化合物抑制微管聚合和/或靶向血管系统，并用于治疗增殖性疾病，如癌症。
• Compounds for the treatment of angiogenesis
  申请人：Wu Yaming

  公开号：US20100093670A1

  公开（公告）日：2010-04-15

  The invention relates to isoxazole, isothiazole, and triazole compounds that are useful for treating or inhibiting angiogenesis.

  该发明涉及对治疗或抑制血管生成有用的异唑、异硫唑和三唑化合物。
• COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
  申请人：Demko Zachary

  公开号：US20100279410A1

  公开（公告）日：2010-11-04

  The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein R a , R b , and R 2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.

  本发明涉及结构式（I）的化合物：或其药学上可接受的盐，溶剂化合物，笼合物和前药，其中Ra，Rb和R2在此定义。这些化合物抑制微管聚合和/或靶向血管系统，可用于治疗增殖性疾病，如癌症。
• 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS
  申请人：Synta Pharmaceuticals Corporation

  公开号：EP1919881A1

  公开（公告）日：2008-05-14